Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals    VRTX

VERTEX PHARMACEUTICALS

(VRTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/26/2020 10/27/2020 10/28/2020 10/29/2020 10/30/2020 Date
207.15(c) 212.19(c) 208.34(c) 207.01(c) 208.36(c) Last
2 087 483 2 756 330 2 221 370 1 931 045 2 828 791 Volume
-2.09% +2.43% -1.81% -0.64% +0.65% Change
More quotes
Financials (USD)
Sales 2020 6 143 M - -
Net income 2020 2 661 M - -
Net cash position 2020 6 120 M - -
P/E ratio 2020 20,7x
Yield 2020 -
Sales 2021 6 926 M - -
Net income 2021 2 675 M - -
Net cash position 2021 9 316 M - -
P/E ratio 2021 20,7x
Yield 2021 -
Capitalization 54 210 M 54 210 M -
EV / Sales 2020 7,83x
EV / Sales 2021 6,48x
Nbr of Employees 3 000
Free-Float 72,2%
More Financials
Company
Vertex Pharmaceuticals specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales break down by type of income as follows: - income from sales of products (99.9%); - royalties and income from partnership, research, and development agreements (0.1%). Net sales break down geographically as follows:... 
More about the company
Notations Surperformance© of Vertex Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
All news about VERTEX PHARMACEUTICALS
10/30VERTEX PHARMACEUTICALS : MA Management's Discussion and Analysis of Financial Co..
AQ
10/30VERTEX PHARMACEUTICALS : Reports Third-Quarter 2020 Financial Results
AQ
10/29VERTEX PHARMACEUTICALS : Q3 2020 Presentation
PU
10/29VERTEX : 3Q Earnings Snapshot
AQ
10/29VERTEX PHARMACEUTICALS INC / MA : Results of Operations and Financial Condition,..
AQ
10/29VERTEX PHARMACEUTICALS : Reports Third-Quarter 2020 Financial Results
BU
10/26VERTEX PHARMACEUTICALS : quaterly earnings release
10/20VERTEX PHARMACEUTICALS : to Announce Third-Quarter 2020 Financial Results on Oct..
AQ
10/19VERTEX PHARMACEUTICALS : to Announce Third-Quarter 2020 Financial Results on Oct..
BU
10/16VERTEX PHARMACEUTICALS : quaterly earnings release
10/15Health Care Down On Rotation To Value Sectors -- Health Care Roundup
DJ
10/15Vertex Shares Plunge After Biotech Drops Closely Watched Drug Prospect
DJ
10/15VERTEX PHARMACEUTICALS : Down After Study Discontinued
DJ
10/15Vertex Pharmaceuticals Down Over 18%, on Pace for Largest Percent Decrease Si..
DJ
10/15Wall Street falls on stalling economic rebound, stimulus impasse
RE
More news
News in other languages on VERTEX PHARMACEUTICALS
10/16VERTEX PHARMACEUTICALS : Veröffentlichung des Quartalsergebnisses
10/16VERTEX PHARMACEUTICALS : publication des résultats trimestriels
09/24VERTEX PHARMACEUTICALS : präsentiert auf virtuellen Mukoviszidose-Konferenzen in..
09/24VERTEX PHARMACEUTICALS : présentera de nouvelles données lors de conférences eur..
07/27VERTEX PHARMACEUTICALS : Veröffentlichung des Halbjahresergebnisses
More news
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 289,71 $
Last Close Price 208,36 $
Spread / Highest target 71,3%
Spread / Average Target 39,0%
Spread / Lowest Target 5,59%
EPS Revisions
Managers
NameTitle
Reshma Kewalramani President, Chief Executive Officer & Director
Jeffrey M. Leiden Executive Chairman
Charles F. Wagner Chief Financial Officer & Executive Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS-4.84%54 210
GILEAD SCIENCES, INC.-10.51%72 904
REGENERON PHARMACEUTICALS44.76%57 199
WUXI APPTEC CO., LTD.71.31%40 863
BEIGENE, LTD.78.89%26 872
GENMAB A/S43.71%21 783